Lilly's New Weekly Insulin Cuts Injections From 365 to 52. It Doesn't Claim to Work Better.

The Food and Drug Administration approved Onswik, Eli Lilly's once-weekly basal insulin for type 2 diabetes, on September 24, 2026. It is only the second once-weekly insulin ever cleared in the United States. The first, Novo Nordisk's Awiqli, reached the market five months earlier, in March.

About one in eight Americans has diabetes, and most of those cases are type 2. Daily insulin has long been the standard treatment for patients whose blood sugar cannot be controlled by pills alone, and daily injections are widely linked to lower long-term adherence. A drug that cuts the shot count from 365 a year to 52 is aimed at that adherence problem specifically, not at controlling blood sugar any better than the insulin already on pharmacy shelves.

Lilly built its case on the QWINT program, four randomized trials enrolling more than 3,400 adults with type 2 diabetes, according to the company's own approval announcement. The trials tested three different starting points: patients who had never used insulin before, patients already on one daily basal shot, and patients already on a daily basal shot plus mealtime insulin. Individual trial sizes ranged from 730 to 986 participants.

What the trials actually showed

In its own approval summary, the FDA said Onswik lowered patients' hemoglobin A1c, the standard three-month measure of blood sugar control, to a similar extent compared with insulin glargine and insulin degludec, the daily basal insulins used as trial comparators. That is the language of non-inferiority, not superiority. Lilly's release describes Onswik's overall safety profile as similar to daily basal insulins as well, with the same class of side effects. Neither company has published a trial comparing Onswik and Awiqli against each other directly.

• Not approved for type 1 diabetes, because of a higher risk of severe hypoglycemia in that population
• Carries a warning for hypokalemia, or low blood potassium
• Carries a warning for fluid retention and heart failure risk when combined with a class of oral diabetes drugs called thiazolidinediones
• Common side effects include injection site reactions, allergic reactions, low blood sugar, and weight gain

A drug class five months old

Novo Nordisk ran a comparably sized program before Awiqli's March 27 approval: the ONWARDS trials, four studies covering 2,680 adults with uncontrolled type 2 diabetes, according to the trade outlet Drug Delivery Business News. Novo Nordisk's chief executive, Mike Doustdar, said at the time that the approval reflected the company's commitment to insulin research "at a time when parts of the industry are stepping back from insulin." Awiqli launched nationally on August 11 and is now available at more than 70,000 U.S. pharmacies and covered by most insurance plans, according to the diabetes advocacy group Beyond Type 1.

“Onswik offers a new once-weekly basal insulin option for patients and reflects our commitment to deliver innovative treatment options that expand choice.”

Lilly has not said exactly when Onswik will reach U.S. pharmacies beyond "coming months," and has not disclosed a price. Reuters reported that Lilly's shares rose about 2.7 percent on the day of the announcement. Onswik has already been approved in Europe, Japan, and Mexico.